Nuvation Bio Inc.
General ticker "NUVB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $871.7M (TTM average)
Nuvation Bio Inc. follows the US Stock Market performance with the rate: 48.0%.
Estimated limits based on current volatility of 2.3%: low 4.76$, high 4.98$
Factors to consider:
- Total employees count: 220 as of 2024
- China accounted for 66.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Regulatory and compliance, Integration challenges, Labor/talent shortage/retention, Economic downturns and volatility, Cybersecurity threats
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.11$, 12.82$]
- 2026-12-31 to 2027-12-31 estimated range: [3.75$, 9.55$]
Financial Metrics affecting the NUVB estimates:
- Negative: with PPE of -15.3 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -5.54 <= 0.07
- Negative: negative Net income
- Positive: 42.60 < Shareholder equity ratio, % of 51.40 <= 64.25
- Negative: Industry earnings per price (median), % of -14.62 <= 0
- Negative: negative Industry operating income (median)
- Positive: Investing cash flow per share per price, % of 3.18 > -0.65
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term NUVB quotes
Long-term NUVB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $7.87MM | $62.90MM |
| Operating Expenses | $99.82MM | $600.50MM | $275.97MM |
| Operating Income | $-99.82MM | $-592.63MM | $-213.06MM |
| Non-Operating Income | $24.02MM | $24.69MM | $8.44MM |
| Interest Expense | $0.00MM | $0.34MM | $13.68MM |
| R&D Expense | $71.29MM | $524.19MM | $115.11MM |
| Income(Loss) | $-75.80MM | $-567.94MM | $-204.63MM |
| Profit(Loss)* | $-75.80MM | $-567.94MM | $-204.63MM |
| Stockholders Equity | $605.12MM | $463.79MM | $305.72MM |
| Inventory | $0.00MM | $0.00MM | $11.41MM |
| Assets | $621.48MM | $540.63MM | $594.82MM |
| Operating Cash Flow | $-68.00MM | $-130.41MM | $-173.43MM |
| Capital expenditure | $0.07MM | $0.16MM | $0.35MM |
| Investing Cash Flow | $8.92MM | $122.70MM | $99.52MM |
| Financing Cash Flow | $0.63MM | $0.33MM | $202.53MM |
| Earnings Per Share** | $-0.35 | $-2.11 | $-0.60 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.